- Home
- NVO vs DHR Comparison
NVO vs DHR Comparison
Compare NVO & DHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVO | DHR |
|---|---|---|
| Founded | 1923 | 1969 |
| Country | Denmark | United States |
| Employees | 69500 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.5B | 166.7B |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | NVO | DHR |
|---|---|---|
| Price | $38.08 | $188.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | $51.00 | ★ $250.56 |
| AVG Volume (30 Days) | ★ 18.6M | 3.5M |
| Earning Date | 01-01-0001 | 04-23-2026 |
| Dividend Yield | ★ 3.17% | 0.66% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 5.05 |
| Revenue | N/A | ★ $19,893,000,000.00 |
| Revenue This Year | N/A | $5.34 |
| Revenue Next Year | $3.30 | $5.84 |
| P/E Ratio | ★ $13.60 | $38.67 |
| Revenue Growth | N/A | ★ 8.53 |
| 52 Week Low | $35.85 | $171.00 |
| 52 Week High | $82.23 | $242.80 |
Technical Indicators
Market Signals| Indicator | NVO | DHR |
|---|---|---|
| Relative Strength Index (RSI) | 32.80 | 22.57 |
| Support Level | $35.85 | $186.18 |
| Resistance Level | $50.30 | $206.93 |
| Average True Range (ATR) | 0.90 | 4.11 |
| MACD | 0.31 | -1.17 |
| Stochastic Oscillator | 42.84 | 0.65 |
Price Performance
Historical ComparisonAbout NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
About DHR Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.